<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01265225</url>
  </required_header>
  <id_info>
    <org_study_id>10.CTIL</org_study_id>
    <nct_id>NCT01265225</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Stem Cell Related Markers</brief_title>
  <official_title>Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Baruch Padeh Medical Center, Poriya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Baruch Padeh Medical Center, Poriya</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the investigators study is to identify a prognostic marker that will evaluate
      the probability of recurrence in patients with stage 0-II breast cancer following surgery to
      remove the tumor.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model:  Case-Only</study_design>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        100 tumor specimens from women with grade 0-11 ductal breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ductal Carcinoma in Situ

          -  DCIS + Microinvasion stages 1 or 11 without positive lymph nodes

        Exclusion Criteria:

          -  tumor specimen with higher than grade II

          -  BRACA 1 or BRACA 2 mutation

          -  Neoadjuvant chemotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baruch PMC</name>
      <address>
        <city>Poriya</city>
        <state>Lower galilee</state>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <lastchanged_date>December 22, 2010</lastchanged_date>
  <firstreceived_date>December 21, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Dr. I. Schnirer</name_title>
    <organization>Baruch Padeh Poriya Medical Center</organization>
  </responsible_party>
  <keyword>breast cancer stages 0-II</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
</clinical_study>
